--- title: "Ocean Biomediacal (OCEA) news: delisting" url: "https://aibio.space/companies/ocean-biomediacal/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OCEA delisting news: Ocean Biomedical's Nasdaq delisting becomes final after board declines review. Ocean Biomediacal, Inc. (OTC: OCEA), United States." --- OCEA Ocean Biomediacal, Inc. OTC · United States # Ocean Biomediacal (OCEA) news OCEA delisting news Distress · 2025-08-14 ## [Ocean Biomedical delays quarterly report for period ended June 30, 2025](https://aibio.space/news/ocean-biomedical-delays-quarterly-report-period-ended-june-30-2025/) The company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date. ## Latest Ocean Biomediacal news 1. 2025-08-05 Listings [Ocean Biomedical's Nasdaq delisting becomes final after board declines review](https://aibio.space/news/ocean-biomedicals-nasdaq-delisting-becomes-final-after-board-declines/) Nasdaq's board declined to review a May 15, 2025 Listing Council decision, making it Nasdaq's final action. The company's chief financial officer and a director have also resigned. ## Ocean Biomediacal at a glance - **Ticker**: OCEA - **Listing**: OTC - **Country**: United States - **Cash, Mar 31, 2025**: $800,000 ### Related companies - [Oric Pharmaceuticals](https://aibio.space/companies/oric-pharmaceuticals/) NASDAQ: ORIC - [Azitra](https://aibio.space/companies/azitra/) AMEX: AZTR - [LENZ Therapeutics](https://aibio.space/companies/lenz-therapeutics/) NASDAQ: LENZ - [Skinvisible](https://aibio.space/companies/skinvisible/) OTC: SKVI - [Scopus Biopharma](https://aibio.space/companies/scopus-biopharma/) OTC: SCPS - [Erasca](https://aibio.space/companies/erasca/) NASDAQ: ERAS - [Braveheart Bio](https://aibio.space/companies/braveheart-bio/) NASDAQ: BRVE - [Pyxis Oncology](https://aibio.space/companies/pyxis-oncology/) NASDAQ: PYXS ### Also on OTC - [EASTGATE BIOTECH CORP](https://aibio.space/companies/eastgate-biotech/) ETBI - [Provectus Biopharmaceuticals](https://aibio.space/companies/provectus-biopharmaceuticals/) PVCT - [Herborium Group](https://aibio.space/companies/herborium/) HBRM - [Vaxart](https://aibio.space/companies/vaxart/) VXRT - [BIOSTAR PHARMACEUTICALS INC](https://aibio.space/companies/biostar-pharmaceuticals/) BSPM - [Lifeloc Technologies](https://aibio.space/companies/lifeloc-technologies/) LCTC ## Ocean Biomediacal annual financials | Line | FY2024 | FY2023 | |---|---|---| | Research and development | [$26,000](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | [$709,000](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | | Net income (loss) | [-$9.5 million](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | [-$114.5 million](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | | Cash from operations | [-$4.2 million](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | [-$9.4 million](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | | Cash and equivalents | [$200,000](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/) | [$1.0 million](https://www.sec.gov/Archives/edgar/data/1869974/000149315224047661/) | Latest balance sheet, Mar 31, 2025 (10-Q): cash and equivalents $800,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ocean Biomediacal Was Ocean Biomediacal delisted? Our latest story on this, dated Aug 5, 2025: "Ocean Biomedical's Nasdaq delisting becomes final after board declines review". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ocean-biomedicals-nasdaq-delisting-becomes-final-after-board-declines/). What is the ticker symbol of Ocean Biomediacal? Ocean Biomediacal, Inc. trades under the ticker OCEA on OTC. Where is Ocean Biomediacal listed? Ocean Biomediacal, Inc. is listed on OTC. What is the SEC CIK of Ocean Biomediacal? The SEC Central Index Key (CIK) for Ocean Biomediacal, Inc. is 1869974. Its filings are on SEC EDGAR. How many shares does Ocean Biomediacal have outstanding? 232,365,143 shares as of 2025-05-15, per the cover page of its 10-Q filed 2025-05-15. Which country or territory is Ocean Biomediacal listed under? Our directory records Ocean Biomediacal, Inc. under United States. What does Ocean Biomediacal do? Our directory classifies Ocean Biomediacal, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ocean Biomediacal? The ISIN recorded for Ocean Biomediacal, Inc. is US67644C1045. Does aibio.space cover Ocean Biomediacal? aibio.space lists Ocean Biomediacal, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ocean Biomediacal incorporated? SEC records list its state or country of incorporation as DE. Is Ocean Biomediacal profitable? Ocean Biomediacal, Inc. reported a net loss of $9.5 million for the fiscal year ended Dec 31, 2024, and used $4.2 million of cash in operations, per its annual report to the SEC. How much does Ocean Biomediacal spend on research and development? $26,000 in the fiscal year ended Dec 31, 2024, per its annual report. How much cash does Ocean Biomediacal have? $800,000 in cash at Mar 31, 2025, per its 10-Q. What is the latest Ocean Biomediacal (OCEA) stock news? Our latest story on Ocean Biomediacal, dated Aug 14, 2025: "Ocean Biomedical delays quarterly report for period ended June 30, 2025". The company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date. [Source](https://aibio.space/news/ocean-biomedical-delays-quarterly-report-period-ended-june-30-2025/). Is Ocean Biomediacal in financial distress? Our latest distress story, dated Aug 14, 2025: "Ocean Biomedical delays quarterly report for period ended June 30, 2025". The company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date. [Source](https://aibio.space/news/ocean-biomedical-delays-quarterly-report-period-ended-june-30-2025/). ## Investor discussion: Ocean Biomediacal Members talk about Ocean Biomediacal (OCEA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ocean Biomediacal, newest first. Each line links the filing it comes from. 1. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225023734/formnt10-q.htm) 2. 2025-08-08 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1869974/000135445725000798/xslF25X02/primary_doc.xml) 3. 2025-08-05 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225022271/form8-k.htm) 4. 2025-07-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225020730/form8-k.htm) 5. 2025-07-16 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225019924/form8-k.htm) 6. 2025-06-13 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225015129/form8-k.htm) 7. 2025-04-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225005788/ex99-1.htm) 8. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225002034/formnt10-k.htm) 9. 2025-04-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000164117225002074/form8-k.htm) 10. 2025-03-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315225011046/form8-k.htm) 11. 2025-02-26 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315225008279/formdef14a.htm) 12. 2025-02-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.02,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315225008395/form8-k.htm) 13. 2025-02-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315225006994/formpre14a.htm) 14. 2025-02-12 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315225006180/form8-k.htm) 15. 2025-01-15 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315225002237/form8-k.htm) 16. 2024-12-17 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315224050414/form8-k.htm) 17. 2024-12-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315224049281/form8-k.htm) 18. 2024-12-06 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315224049099/form8-k.htm) 19. 2024-11-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1869974/000149315224047421/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:OCEA on TradingView](https://www.tradingview.com/symbols/OTC-OCEA/). ## SEC filings and registration - **SEC name**: Ocean Biomedical, Inc. - **CIK**: 1869974 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OCEA (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 515 MADISON AVE SUITE 8078, NEW YORK, NY, 10022 - **Phone**: (646) 908-2658 - **Shares outstanding**: 232,365,143 as of 2025-05-15 (10-Q filed 2025-05-15) - **Former names**: Ocean Biomedical, Inc./DE; Aesther Healthcare Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225022271/form8-k.htm) filed 2025-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225020730/form8-k.htm) filed 2025-07-23 - [8-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225019924/form8-k.htm) filed 2025-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225015129/form8-k.htm) filed 2025-06-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1869974/000164117225011080/form10-q.htm) filed 2025-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225005788/form8-k.htm) filed 2025-04-23 - [10-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225003155/form10-k.htm) filed 2025-04-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1869974/000164117225002074/form8-k.htm) filed 2025-04-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001869974), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ocean Biomediacal, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker OCEA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ocean Biomediacal, Inc. - **Ticker**: OCEA - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US67644C1045 - **Last quote in directory**: 2026-10-20 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-OCEA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ocean-biomediacal/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ocean Biomediacal (OCEA) news: delisting", 2026-10-31, https://aibio.space/companies/ocean-biomediacal/